Cibus (CBUS) Research & Development (2016 - 2026)
Cibus (CBUS) posted Research & Development of $9.4 million for Q4 2025, down 12.95% sequentially from $10.8 million in Q3 2025, and down 24.5% YoY from $12.4 million in Q4 2024.
Cibus (CBUS) Research & Development (2016 - 2026) Analysis & Trends
Cibus has reported Research & Development for 10 years, with the latest figure at $9.4 million in Q4 2025.
- Quarterly Research & Development fell 24.5% year-over-year to $9.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.2 million (down 12.36% YoY) and the FY2025 annual result came in at $44.2 million, down 12.36% from the prior year.
- Research & Development slipped to $9.4 million in Q4 2025 per CBUS's latest filing, from $10.8 million in the prior quarter.
- Over five years, Research & Development peaked at $17.5 million in Q3 2023 and troughed at $2.2 million in Q1 2023.
- A 5-year average of $8.0 million and a median of $8.9 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 505.63% in 2023, down 30.53% in 2023.
- Over 5 years, Research & Development stood at $2.9 million in 2021, then dropped by 18.03% to $2.3 million in 2022, then surged by 505.63% to $14.2 million in 2023, then decreased by 12.49% to $12.4 million in 2024, then decreased by 24.5% to $9.4 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $9.4 million, $10.8 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | 8.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.51 Mn |
| Dec 31, 2025 | 9.39 Mn |
| Sep 30, 2025 | 10.78 Mn |
| Jun 30, 2025 | 12.23 Mn |
| Mar 31, 2025 | 11.80 Mn |
| Dec 31, 2024 | 12.43 Mn |
| Sep 30, 2024 | 12.99 Mn |
| Jun 30, 2024 | 12.99 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | 14.21 Mn |
| Sep 30, 2023 | 17.52 Mn |
| Jun 30, 2023 | 8.43 Mn |
| Mar 31, 2023 | 2.21 Mn |
| Dec 31, 2022 | 2.35 Mn |
| Sep 30, 2022 | 3.02 Mn |
| Jun 30, 2022 | 3.25 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 2.86 Mn |
| Sep 30, 2021 | 2.58 Mn |
| Jun 30, 2021 | 2.84 Mn |